For the Quarter Ending March 2025
North America
In Q1 2025, the methenamine market in North America maintained a stable pricing trend, supported by sustained demand and steady supply fundamentals. The pharmaceutical sector, a key consumer, continued to show consistent uptake, particularly for methenamine-based treatments used in urinary tract health. This was reinforced by increasing awareness and prescriptions, driven in part by a growing elderly population more prone to such conditions.
On the supply side, availability remained uninterrupted as generic drug manufacturers, particularly from India, continued to meet regulatory benchmarks and expand their portfolio in the U.S. market. This ensured a healthy flow of product despite broader global logistic constraints.
While upstream volatility in raw material prices—especially for formaldehyde and ammonia—posed moderate cost pressures, the overall impact was contained by stable production operations and predictable demand from core application areas.
Overall, Q1 2025 reflected a balanced methenamine market in the U.S., underpinned by steady pharmaceutical demand, reliable supply chains, and manageable input costs, contributing to pricing resilience.
APAC
In Q1 2025, the Methenamine market in the APAC region—particularly in China—exhibited a predominantly stable to bearish pricing trend. The quarter began with modest price declines due to weak demand across key sectors, especially agrochemicals and automotive, coupled with high inventory levels and reduced logistics costs. Although pharmaceutical demand showed resilience, it was insufficient to offset the downward pressure created by the seasonal lull and oversupply. As the quarter progressed, production resumed post-Lunar New Year, but manufacturers operated at reduced capacities due to maintenance and regulatory constraints, keeping supply in check. February saw momentary price support from tighter supply and firm pharmaceutical demand. By March, a balanced supply-demand dynamic returned, supported by expanding industrial activity and stable downstream consumption, particularly in automotive thermosetting resins and generic drug production. Raw material costs fluctuated slightly, but their impact remained muted due to controlled production rates.
Compared to Q4 2024, when Methenamine prices rose by 5.5% amid robust pharmaceutical demand, Q1 2025 marked a shift to a more cautious and stable market. Weaker automotive recovery and seasonal slowdowns tempered price momentum, leading to a flatter overall trend.
Europe
In Q1 2025, Methenamine prices in the European region, particularly Russia, exhibited a mixed but overall stable to slightly bullish trend, reflecting changing dynamics in supply, demand, and feedstock costs. January started with a softening trend as prices dropped due to sluggish demand, particularly in the agrochemical sector, and rising inventory levels. However, prices found a temporary floor by the end of the month amid balanced supply-demand fundamentals. Moving into February, market conditions improved, driven by rising raw material costs, logistical constraints, and a sharp uptick in demand from the automotive and pharmaceutical sectors. Methenamine prices climbed gradually, gaining around 5.5% through the month. This bullish phase was sustained by increasing industrial activity, higher energy and feedstock prices, and tight availability. By March, prices stabilized at these elevated levels as steady demand from the pharmaceutical sector and firm raw material trends offset slowing automotive consumption and broader economic headwinds. Compared to Q4 2024, where prices were largely in a downward spiral due to weaker demand and falling costs, Q1 2025 marked a modest recovery phase with stronger fundamentals and renewed pricing support across Russia.
MEA
In Q1 2025, the Methenamine market in the MEA region, particularly Saudi Arabia, displayed an overall stable to slightly bearish price trend, reflecting dynamic but largely balanced supply-demand conditions. The quarter began with a significant price decline in January, driven by subdued demand from the agrochemical and pharmaceutical sectors, coupled with high inventory levels and a global oversupply. Weak procurement activity and adverse weather disruptions added downward pressure, leading to price drops of over 10% in total during January. However, the bearish sentiment began to ease in February as trading normalized, and stronger demand from the resin and rubber sectors prompted a modest rebound in prices. This recovery was supported by steady export interest and minor supply constraints. By March, the market stabilized, with prices holding firm. Balanced feedstock costs and consistent domestic production levels ensured adequate supply, while the pharmaceutical and automotive sectors offered steady consumption. Compared to Q4 2024, which saw sharper volatility and weaker fundamentals, Q1 2025 was relatively more stable, with limited price fluctuations after the initial January dip.
For the Quarter Ending December 2024
North America
In the fourth quarter of 2024, the methenamine market in North America experienced a period of stabilization and modest growth. The market was influenced by several key factors, including demand dynamics, feedstock costs, and industry-specific developments. The pharmaceutical sector, a significant consumer of methenamine, maintained steady demand due to its use as a urinary antiseptic. This consistent demand provided a stable foundation for the market. Conversely, the rubber industry faced challenges, leading to reduced demand, and contributing to market complexities.
Additionally, fluctuations in feedstock prices, particularly for formaldehyde and ammonia, added to the pricing intricacies, affecting production costs and overall market dynamics. Despite these challenges, the methenamine market in North America demonstrated resilience. The pharmaceutical industry's stable demand and the rubber sector's recovery efforts contributed to a balanced market environment. The interplay between feedstock costs and sector-specific demands underscored the market's complexity during this period.
Overall, the fourth quarter of 2024 in North America was characterized by a delicate balance between steady demand from the pharmaceutical sector and challenges in the rubber industry, with feedstock price fluctuations adding complexity to the market landscape.
APAC
In the fourth quarter of 2024, the methenamine market in the APAC region, particularly in China, experienced a steady and robust upward trend, with a quarter-on-quarter rise of 5.5%. The increase in prices was largely driven by the growing demand from the pharmaceutical sector, as Chinese pharmaceutical companies expanded both domestically and internationally, notably in Africa. This surge in demand was a significant factor, as methenamine is used in the production of pharmaceutical products, especially as a urinary antiseptic. Despite fluctuations in the prices of feedstocks, such as formaldehyde, which remained stable, and ammonia, which experienced a decline, the overall demand from the pharmaceutical industry kept prices on an upward trajectory. The agricultural sector also contributed to the demand, with Chinese pesticide manufacturers raising prices due to rising raw material costs and stricter environmental regulations. This upward price movement was coupled with declining inventory levels, creating upward pressure despite the declining production costs driven by ammonia prices. The market also witnessed increased innovation in the pharmaceutical sector, further boosting demand. The combination of growing demand, especially in the pharmaceutical industry, and stable supply dynamics contributed to a positive market sentiment, resulting in an overall increase in methenamine prices during Q4 2024.
Europe
In the fourth quarter of 2024, the methenamine market in Russia experienced a significant quarter-on-quarter rise of 11.7%, driven by steady demand and favourable conditions in the pharmaceutical sector. The prices of methenamine witnessed a consistent uptick, primarily due to increased demand from downstream sectors, particularly the pharmaceutical industry, which continued to show robust growth. This demand was fuelled by rising drug prices and higher consumption in the domestic market. Despite stable feedstock prices, such as ammonia, which helped maintain steady production costs, the overall demand dynamics were bullish. The Russian pharmaceutical market played a pivotal role in this trend, exhibiting resilience and growth despite economic challenges. Sales in the sector grew significantly, with a 16.6% increase in the retail segment from January to October 2024. The pharmaceutical market's expansion, particularly in retail, boosted methenamine demand as it is essential in the production of various pharmaceutical products. Additionally, the manufacturing sector showed a slight rebound, further supporting the bullish market sentiment for methenamine. The steady supply, coupled with increased procurement activities, led to the continued price increases throughout Q4 2024.
MEA
In the fourth quarter of 2024, the methenamine market in Saudi Arabia saw a significant quarter-on-quarter rise of 6.8%, driven primarily by strong demand from key downstream sectors such as pharmaceuticals and agrochemicals. The prices of methenamine steadily increased throughout the quarter, reflecting heightened consumption, especially within the pharmaceutical industry. The robust demand from this sector was further fuelled by the government’s ongoing efforts to bolster its healthcare system under the Vision 2030 initiative, which has led to increased investments and production capacity expansion. The Saudi Arabian pharmaceutical sector experienced significant growth, with major players like Saudi Pharmaceutical Industries reporting a notable rise in their financial results. Government initiatives aimed at localizing pharmaceutical production also contributed to the demand for methenamine. Additionally, two memorandums of understanding (MOUs) were signed with Chinese healthcare firms, further strengthening the sector’s prospects. Despite fluctuations in feedstock prices, particularly ammonia, the market remained bullish due to low inventory levels and consistent demand. The sector also benefited from strong growth in non-oil business sectors, which helped sustain the overall positive market dynamics. The demand outlook for methenamine remains robust, bolstered by the expansion of both the pharmaceutical and agrochemical sectors.
For the Quarter Ending September 2024
North America
In Q3 2024, the Methenamine market in North America experienced several key trends. Prices declined due to reduced demand from the fertilizer industry and logistical challenges, such as bottlenecks in export shipments via the Panama Canal. The ongoing drought conditions also impacted the market, leading to an accumulation of inventories.
The demand for Methenamine remained subdued, primarily due to cautious purchasing behaviour from consumers and weak performance in the fertilizer sector. The pharmaceutical sector also showed moderate demand. The supply chain faced challenges, including delays in shipments and limited vessel transits through the Panama Canal.
Despite these challenges, the supply remained relatively steady. The market is expected to face continued pressure from logistical challenges and subdued demand. However, there may be opportunities for recovery if demand from the pharmaceutical and fertilizer sectors improves.
APAC
In Q3 2024, the Methenamine market in the APAC region experienced a significant uptrend in prices, driven by multiple factors. The sustained increase was primarily influenced by robust demand from various sectors like pharmaceuticals, agriculture, and textiles. Additionally, regulatory reforms aimed at streamlining drug manufacturing processes further bolstered market sentiment, fostering partnerships between local and foreign companies. These initiatives enhanced production efficiencies and supported the overall price surge. China, being a key player in the Methenamine market, witnessed the most substantial price changes during this period. The market exhibited strong seasonality, with prices showing a notable positive correlation with increased domestic demand and stable feedstock costs. Notably, the price increase of 3% from the previous quarter highlighted the market's resilience and adaptability to changing dynamics. Despite a -7% decrease compared to the same quarter last year, the gradual recovery and price stabilization were evident. The price comparison between the first and second half of the quarter further emphasized the steady upward trend. The quarter-ending price of USD 910/MT of Hexamethylenetetramine CIF Lianyungang in China underscored the overall positive pricing environment and the market's ability to navigate challenges effectively.
Europe
In Q3 2024, Methenamine pricing in Europe exhibited a predominantly upward trend, driven by several critical factors. The escalating costs of raw materials, notably ammonia, have substantially influenced the production expenses, leading to a ripple effect on Methenamine prices. Additionally, heightened demand from the pharmaceutical and automotive sectors contributed to price increments. This demand surge is attributed to increased domestic production and strategic shifts towards self-sufficiency, particularly in response to international trade dynamics and supply chain disruptions. Russia, in particular, has experienced the most pronounced price changes, with Methenamine prices reflecting significant volatility. The overall trend in Russia was positive, underscored by a 5% increase from the previous quarter, illustrating a robust market environment. This upward trajectory was further accentuated by seasonal factors, as the second half of the quarter saw a 6% increase in prices compared to the first half. Despite a -1% change from the same quarter last year, the overall pricing sentiment remained positive, supported by strategic supply management and increased trading activities. The quarter concluded with Methenamine prices reaching USD 790/MT FOB Novosibirsk, indicating a strong market position despite historical fluctuations. The consistent price increase during this quarter underscores a resilient and adaptive market, driven by strategic economic maneuvers and sector-specific demands.
MEA
In Q3 2024, Methenamine pricing in the MEA region experienced an upward trajectory, driven by several key factors. The notable increase in demand for pharmaceutical chemicals, including Methenamine, played a crucial role in pushing market prices higher. This heightened demand was fueled by initiatives aimed at boosting domestic manufacturing and reducing reliance on imports, creating a more favourable pricing environment. Within Saudi Arabia, Methenamine prices saw significant fluctuations, with a 1% increase from the previous quarter. This surge in prices marked a stark contrast to the -7% decline observed from the same quarter last year, indicating a notable shift in market dynamics. The price comparison between the first and second half of the quarter revealed a 3% increase, underlining the consistent upward trend observed in pricing. The quarter-ending price of USD 835/MT for Hexamethylenetetramine FOB Al Jubail in Saudi Arabia reflected the peak of this positive price trend in the region.
For the Quarter Ending June 2024
North America
In the USA, the market for Methenamine is facing challenges despite mixed sectoral dynamics. The rubber industry is experiencing a downturn, negatively impacting the overall demand for Methenamine. However, the pharmaceutical sector remains positive, providing some support to Methenamine demand due to its application as a urinary tract antiseptic.
Feedstock price movements have added complexity to the market. Formaldehyde prices have surged by 29.6% in Q2, increasing the production costs for Methenamine, while ammonia prices have decreased by 8.8%, slightly offsetting the overall cost pressure. The combination of high formaldehyde costs and decreased ammonia prices has created a volatile pricing environment. This challenging market landscape for Methenamine is further complicated by the decreased demand in the rubber sector and sustained demand from the pharmaceutical industry.
The current scenario reflects the intricate balance between feedstock cost fluctuations and sector-specific demand trends, making the Methenamine market in the USA difficult to navigate. As a result, market participants are closely monitoring these variables to manage inventory and pricing strategies effectively.
APAC
In Q2 2024, the pricing environment for Methenamine in the APAC region remained stable, driven by a confluence of market factors primarily affecting supply and demand dynamics. Despite seasonal fluctuations and varying market sentiments, the overall stability can be attributed to balanced supply chains and moderated demand from key sectors. The Methenamine market experienced a 12.9% decline compared to the same quarter last year, reflecting a long-term trend of decreasing prices. However, this quarter saw a 4.3% reduction from the previous quarter in 2024, indicating a stabilization phase following previous volatility. Focusing on China, Methenamine prices exhibited notable fluctuations, albeit within a stable context. Seasonal demand shifts, particularly in the pharmaceutical and food additives sectors, played a significant role in price adjustments. The quarter ended with Methenamine prices in China at USD 869/MT CIF Lianyungang, reflecting a consistent pricing environment characterized by cautious market optimism. Overall, the stable sentiment in Methenamine pricing for Q2 2024 is shaped by a combination of strong inventory levels, balanced supply-demand dynamics, and moderated market activities. Despite minor fluctuations, the market has managed to maintain equilibrium, suggesting a stable pricing environment with neither significant upward nor downward pressure on Methenamine prices. The latest pricing confirms this stability, presenting a positive outlook for market participants.
Europe
In the European market, the Methenamine landscape is currently facing challenges, with contrasting trends in its primary sectors. The rubber industry is showing positive growth, which helps to support the demand for Methenamine as a vulcanization accelerator. However, the pharmaceutical sector is experiencing a downturn, which negatively impacts Methenamine demand as it is used in urinary antiseptics. Additionally, feedstock prices have shown significant changes in Q2; formaldehyde prices have decreased by 4.8%, and ammonia prices have dropped by 9.7%. These declines in feedstock prices should theoretically reduce production costs for Methenamine, but the overall market remains complex. The reduction in costs is being offset by the lower demand from the pharmaceutical sector. The combination of these factors has created a challenging pricing environment for Methenamine in Europe. This complexity requires market participants to carefully manage their inventory and pricing strategies to navigate the fluctuating demand and cost dynamics effectively. The current market dynamics highlight the intricate balance between sectoral demand and feedstock price movements that define the Methenamine market in Europe.
MEA
The second quarter of 2024 has been challenging for the Methenamine market in the MEA region, with a consistent downward pricing trend. Several factors have contributed to this decline, primarily driven by reduced demand from key downstream industries, such as pharmaceuticals, polymers, rubber, and textiles. The economic slowdown in major importing countries has exacerbated the situation, leading to diminished export orders and a subsequent accumulation of inventories. Additionally, the stability or slight decline in the prices of key feedstocks, such as formaldehyde and ammonia, has removed any upward pressure on Methenamine prices, further contributing to the bearish market sentiment. In Saudi Arabia, the Methenamine market has experienced the most significant price changes within the region. The overall trend for this quarter has been characterized by decreasing prices, influenced by lower consumer demand and high inventory levels. Seasonality also played a role, with summer typically seeing heightened demand, which did not materialize as expected this year. Compared to the same quarter last year, Methenamine prices have fallen by 10.6%, illustrating a marked decline. From the previous quarter in 2024, the prices have decreased by 4.2%, reflecting a persistent downward trajectory. Within this quarter alone, the price comparison between the first and second half shows a 3% drop, indicating no signs of recovery. The latest quarter-ending price for Methenamine in Saudi Arabia stands at USD 786/MT FOB Al Jubail.
